StockWatch
·
DISHMAN CARBOGEN AMCIS LTD · QQ2 FY-2027 · THE CALL

Severe miss masks optimistic medium-term plan

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsDCALDishman Carbogen Amcis Ltd20 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade C

FY26 guidance (19.5-20% EBITDA, ₹500 Cr India revenue in 12-18 months) missed. FY27 margin cut from 19.5-20% to 15-16% guidance.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Q2 FY27 delivered a 22% revenue decline and -₹67 Cr net loss, missing prior 19.5-20% EBITDA margin guidance by over 1,000 bps. Management blamed external biotech funding constraints and acknowledged "soft quarter," but offered medium-term targets (FY28-29: 10-12% growth, 20-21% margins) dependent on uncertain execution—Bavla facility ramp, tech transfer validation (April 2027), and molecule pipeline recovery. High execution risk on guidance given track record of prior-year misses.

₹507.4 Cr

Revenue · −22.3% YoY

₹-66.7 Cr

Reported PAT · −202.2% YoY

Compressing

Margins · vs guidance: Overstated

Did the claims hold up?

Management's claims vs. the numbers

Market trends slightly upwards, early phase projects showing interest

MISS

Development revenue declined; multiple projects deferred due to biotech funding constraints

CDMO margins stable, optimization underway

MISS

CDMO margins fell 12.3% from 25% YoY; Marketable Molecules 8.7% from 21% H1 YoY

Order book building for H2 and next year

Partial

Q2 showed -22% revenue; first half ₹1,185 Cr vs last year ₹1,360 Cr. Orders deferred to H2 or next year

Bavla facility achieving significant cost leverage

OVERSTATED

Bavla still in infrastructure/setup phase; targeting ₹150 Cr quarterly run-rate but no timeline given

EBITDA margin FY27 around 15-16% full year

OVERSTATED

Q2 OPM 9.1%, H1 EBITDA ₹106 Cr on ₹1,185 Cr revenue = 8.9%. Margin path suggests miss on 15-16% target

Earnings quality

What changed since the last call

Deltas vs. the prior call

EBITDA margin guidance cut

Downgrade

FY26 guided 19.5-20%; FY27 guided 15-16%. 400-500 bps miss signals sustained margin pressure vs prior year.

Biotech funding constraints emerged

New

AI bubble diversion, funding delays caused molecule development revenue to stall. Orders deferred to H2 FY27 and beyond. Not flagged in prior call.

Bavla facility ramp expectations reset

Downgrade

Prior calls implied faster scale-up; now targeting ₹150 Cr quarterly but no timeline. Analyst Smit Shah challenged why no progress after 20+ years CDMO.

The Q&A

Analysts pressed hard on three fronts: (1) Bavla delays despite decades of CDMO experience; (2) Why margins collapsed while costs fixed; (3) Execution urgency on funding & tech transfers. Management blamed external constraints (biotech funding, molecule availability), defended medium-term strategy, but offered no near-term operational upside. Tone was defensive.

The exchanges that mattered

Bavla capacity utilization — Smit Shah, JHP Securities

Partial

Business is lumpy, dependent on molecule development. Historically targeted small biotech; now pursuing big pharma and Phase III. Strategy adjusted to tackle early phase. Time to commercialize is 5-10 years; we're accelerating to 2 years in certain cases. Market is now more open and customers more willing.

Interest cost trajectory — Harshit Rathi, Neogen Advisory

Answered

ECB deployment completing. Expected drawdown before Christmas; if not, by Q4/Q1 next year. Interest should drop to ₹20-25 Cr quarterly from full deployment.

H1 revenue miss root cause — Tarang Agarwal, Old Bridge Asset Management

Answered

Early-phase development work was dry due to biotech funding diversion to AI. Pipeline gap expected from Q1 onwards. Order book now building for H2+. Some orders deferred to next year. This is temporary; medium-term growth intact.

Medium-term improvement timing — Tarang Agarwal, Old Bridge Asset Management

Dodged

Assets, organization, and leadership in place. Challenge is utilizing assets and changing market reputation from small-scale to big-pharma CDMO. This takes time—maybe longer than in past. No specific timeline, but confidence in strategy.

Biotech funding impact on dev revenues — Ojas Mehta, Sunk Cost Fallacy Capital

Partial

Funding environment slow but expected to improve. Focusing on winning more business, becoming second supplier, right-sizing capacity. Cost control ongoing across group.

Severity of Q2 miss — Vivian Joshi

Partial

Unusual quarter. Orders expected to complete by end-September didn't. Biotech companies funding-constrained and unable to progress molecules. Orders deferred to H2 FY27 and beyond. Execution is on track.

Execution urgency — Vivian Joshi

Dodged

Family agreement and multi-jurisdictional funding processes caused delays. These are process steps, not operational failures. No impact on financial performance. Confident of completion next month.

FY27 revenue target — Vivek Kumar

Dodged

Not expecting growth over last year. But will be closer to ₹2,900 Cr by end of year.

Operating profit match last year — Vivek Kumar

Partial

Will be lower due to fixed costs and revenue composition (Marketable Molecules shifted to lower-margin cholesterol from vitamin D analogs). Difficult to mention right now. Vitamin D recovery expected H2.

FY28-29 growth outlook — Harshit Rathi, Neogen Advisory (follow-up)

Answered

FY28-29: At least 10-12% growth on yearly basis. EBITDA margin in excess of 20-21%. Depends on current year close, but medium-term growth intact.

Bavla commercial molecule value — Smit Shah, JHP Securities (follow-up)

Answered

Yearly run rate could be close to CHF 15-20 million.

Tech transfer annualized revenue — Tarang Agarwal, Old Bridge Asset Management (final)

Answered

Roughly CHF 30 million or something like that. Really roughly, because contract negotiation ongoing. Assumption around CHF 25-30M.

Guidance

Forward guidance and management's confidence

FY28-29: At least 10-12% growth YoY

Medium

Assumes tech transfer ramp (CHF 25-30M), Bavla ₹150 Cr quarterly, molecule pipeline recovery. Timing vague; execution risk high.

FY27 (current year): 'Closer to ₹2,900 Cr by end of year'

Low

H1 ₹1,185 Cr (13% below last year ₹1,360 Cr). Full year implies ₹2,370-2,500 Cr, below ₹2,900 Cr last year.

Bavla: Target ₹150 Cr quarterly run rate

Low

Infrastructure complete but no timeline given. Japanese project, tech transfers still in validation phase. Unclear when meaningful revenue materializes.

FY27 EBITDA margin: 15-16% full year

Low

Q2 actual 9.1% OPM, H1 ~8.9% (106 Cr ÷ 1,185 Cr). Path to 15-16% requires significant H2 recovery with minimal upside shown.

FY28-29 EBITDA margin: Excess of 20-21%

Medium

Implies 500-700 bps margin improvement. Depends on Bavla ramp, revenue scale, and cost leverage. Prior miss on 19.5-20% FY26 guidance.

FY27 CapEx: ~₹200 Cr

High

Q1-Q2 CapEx $10.3M (~₹85 Cr annualized run rate). Bavla water facility completed; digital transformation (SAP) ongoing.

Risks the call surfaced

Ranked by how much they should concern a holder

Biotech funding cycle risk

High

Biotech companies funding-constrained; molecule development work stalled, orders deferred to H2 FY27+. AI bubble diverted capital. Directly caused Q2 revenue miss.

Margin compression structural

High

CDMO margin fell 12.3% from 25% YoY; Marketable Molecules 8.7% from 21% H1. Fixed costs not scaling with revenue decline. If revenue stays depressed, margins may not recover to prior levels.

Bavla facility utilization risk

High

Bavla capex completed but facility underutilized. Targeting ₹150 Cr quarterly run-rate but no timeline. Japanese project validation incomplete. If ramp-up delays, ROI erodes.

Tech transfer execution risk

High

3 commercial, 2 intermediate, KSMs in transfer pipeline. Validation batches scheduled April 2027. Any regulatory or technical delays push revenue 3-6+ months. Expected CHF 25-30M annual revenue at risk.

Guidance credibility erosion

High

FY26 guidance 19.5-20% EBITDA margin missed (actual ~16-17%). ₹500 Cr India revenue target missed. FY27 15-16% margin guidance also at risk (H1 actual 8.9%). Analyst pushback on execution credibility evident.

Management

Score 5/10. Acknowledged "soft quarter" but heavily defended via external constraints (biotech funding, molecule availability). Limited transparency on specific timelines for Bavla, tech transfers. Some evasion on operating profit match and FY27 revenue target. Track record mixed. FY26 margin guidance (19.5-20%) and ₹500 Cr India revenue targets missed. H1 FY27 missed 15-16% margin guidance (8.9% actual). Multiple prior-year initiatives (Bavla, tech transfers) taking longer than expected.

What to watch next
  • 1 · Mar-Apr 2027

    Tech transfer validation batches complete; client filing expected

  • 2 · Q4 FY27

    ECB drawdown finalized; interest cost drop ₹40 Cr → ₹20-25 Cr quarterly

  • 3 · H2 FY27+

    Vitamin D analogs, Phase III molecule ramp, deferred orders recovery

High execution risk on guidance given track record of prior-year misses.

Informational and educational content only. Not investment advice.